Grace Therapeutics, Inc. Effective Tax Rate
Grace Therapeutics, Inc. (GRCE) reported Effective Tax Rate of 0.00% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateContinuingOperations · last filed 2026-08-13
- Grace Therapeutics, Inc. effective income tax rate reconciliation, percent for the quarter ending 2026-06-30 was 0.00%.
- Grace Therapeutics, Inc. effective income tax rate reconciliation, percent for the quarter ending 2025-12-31 was 0.00%, a 100.00% decline year-over-year.
- Grace Therapeutics, Inc. effective income tax rate reconciliation, percent for the quarter ending 2025-09-30 was 0.00%, a 100.00% decline year-over-year.
- Grace Therapeutics, Inc. effective income tax rate reconciliation, percent for the quarter ending 2025-06-30 was 0.00%, a 100.00% decline year-over-year.
- Grace Therapeutics, Inc. effective income tax rate reconciliation, percent for fiscal 2026 was 17.92%, a 28.49% decline from fiscal 2025.
- Grace Therapeutics, Inc. effective income tax rate reconciliation, percent for fiscal 2025 was 25.06%, a 100.96% increase from fiscal 2024.
- Grace Therapeutics, Inc. effective income tax rate reconciliation, percent for fiscal 2024 was 12.47%.
| Period end | Effective Income Tax Rate Reconciliation, Percent 3 month | Effective Income Tax Rate Reconciliation, Percent 6 month | Effective Income Tax Rate Reconciliation, Percent 9 month | Effective Income Tax Rate Reconciliation, Percent 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00% 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | 17.92% 10-K · filed 2026-06-18 | |||
| 2025-12-31 | 0.00% 10-Q · filed 2026-02-12 | 0.00% 10-Q · filed 2026-02-12 | ||
| 2025-09-30 | 0.00% 10-Q · filed 2025-11-13 | 0.00% 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | 0.00% 10-Q · filed 2026-08-13 | |||
| 2025-03-31 | 25.06% 10-K · filed 2026-06-18 | |||
| 2024-12-31 | 12.70% 10-Q · filed 2026-02-12 | 17.60% 10-Q · filed 2026-02-12 | ||
| 2024-09-30 | 19.90% 10-Q · filed 2025-11-13 | 20.70% 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | 21.67% 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | 12.47% 10-K · filed 2025-06-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |